Close Menu

NEW YORK – In the days since the US Food and Drug Administration granted approval for Bristol Myers Squibb's nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for non-small cell lung cancer, the question as to where this new option fits into the lung cancer immunotherapy landscape has been top of mind for many oncologists.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
May
27
Sponsored by
Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments.